Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.73% | 25.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.73% | 25.39% | |||
| Cost of Revenue | -7.94% | 11.94% | |||
| Gross Profit | 5.99% | 30.16% | |||
| SG&A Expenses | 2.44% | 15.49% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.45% | 11.19% | |||
| Operating Income | 7.54% | 39.21% | |||
| Income Before Tax | 7.91% | 40.26% | |||
| Income Tax Expenses | 46.44% | 14.85% | |||
| Earnings from Continuing Operations | 0.00% | 46.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 46.94% | |||
| EBIT | 7.54% | 39.21% | |||
| EBITDA | 6.78% | 33.87% | |||
| EPS Basic | 0.35% | 47.25% | |||
| Normalized Basic EPS | 6.83% | 40.56% | |||
| EPS Diluted | 1.12% | 45.83% | |||
| Normalized Diluted EPS | 7.41% | 39.28% | |||
| Average Basic Shares Outstanding | -0.35% | -0.21% | |||
| Average Diluted Shares Outstanding | -0.89% | 0.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
